Eric Lévesque MD, Ph.D

Associate Professor, Laval University, Faculty of Medicine
CIHR Clinician-Scientist

MD Internal medicine, Hematology/Oncology
Bachelor in biochemistry, M.Sc. and Ph.D. degree in Molecular Oncology

Joined in for a post-doc: 2006-2010;

Now an independant investigator

Research projects in the area of oncology, cancer, endocrinology (translational and clinical studies)


List of publications (see Pubmed)

Selected publications

Lacombe L, Fradet V, Lévesque É, Pouliot F, Larue H, Bergeron A, Hovington H,
Caron A, Nguile-Makao M, Harvey M, Fradet Y, Guillemette C. Phase II
Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of
Non-Muscle-Invasive Bladder Cancer: A Gene-Smoking Interaction. Cancer Prev Res
(Phila). 2016 Feb;9(2):189-95. doi: 10.1158/1940-6207.CAPR-15-0069. Epub 2015 Dec
8. PubMed PMID: 26645279.


Margaillan G, Lévesque É, Guillemette C. Epigenetic regulation of steroid
inactivating UDP-glucuronosyltransferases by microRNAs in prostate cancer. J
Steroid Biochem Mol Biol. 2016 Jan;155(Pt A):85-93. doi:
10.1016/j.jsbmb.2015.09.021. Epub 2015 Sep 15. PubMed PMID: 26385605.


Chen S, Villeneuve L, Jonker D, Couture F, Laverdière I, Cecchin E, Innocenti
F, Toffoli G, Lévesque E, Guillemette C. ABCC5 and ABCG1 polymorphisms predict
irinotecan-induced severe toxicity in metastatic colorectal cancer patients.
Pharmacogenet Genomics. 2015 Dec;25(12):573-83. doi:
10.1097/FPC.0000000000000168. PubMed PMID: 26352872.


Belledant A, Hovington H, Garcia L, Caron P, Brisson H, Villeneuve L, Simonyan
D, Têtu B, Fradet Y, Lacombe L, Guillemette C, Lévesque E. The UGT2B28
Sex-steroid Inactivation Pathway Is a Regulator of Steroidogenesis and Modifies
the Risk of Prostate Cancer Progression. Eur Urol. 2016 Apr;69(4):601-9. doi:
10.1016/j.eururo.2015.06.054. Epub 2015 Jul 26. PubMed PMID: 26215610.


Tourancheau A, Margaillan G, Rouleau M, Gilbert I, Villeneuve L, Lévesque E,
Droit A, Guillemette C. Unravelling the transcriptomic landscape of the major
phase II UDP-glucuronosyltransferase drug metabolizing pathway using targeted RNA
sequencing. Pharmacogenomics J. 2016 Feb;16(1):60-70. doi: 10.1038/tpj.2015.20.
Epub 2015 Apr 14. PubMed PMID: 25869014.


Chen S, Laverdiere I, Tourancheau A, Jonker D, Couture F, Cecchin E,
Villeneuve L, Harvey M, Court MH, Innocenti F, Toffoli G, Lévesque E, Guillemette
C. A novel UGT1 marker associated with better tolerance against
irinotecan-induced severe neutropenia in metastatic colorectal cancer patients.
Pharmacogenomics J. 2015 Dec;15(6):513-20. doi: 10.1038/tpj.2015.12. Epub 2015
Mar 17. PubMed PMID: 25778466.


Laverdière I, Flageole C, Audet-Walsh É, Caron P, Fradet Y, Lacombe L,
Lévesque É, Guillemette C. The UGT1 locus is a determinant of prostate cancer
recurrence after prostatectomy. Endocr Relat Cancer. 2015 Feb;22(1):77-85. doi:
10.1530/ERC-14-0423. Epub 2014 Dec 1. PubMed PMID: 25452636.


Laverdière I, Guillemette C, Tamouza R, Loiseau P, Peffault de Latour R, Robin
M, Couture F, Filion A, Lalancette M, Tourancheau A, Charron D, Socié G, Lévesque
É. Cyclosporine and methotrexate-related pharmacogenomic predictors of acute
graft-versus-host disease. Haematologica. 2015 Feb;100(2):275-83. doi:
10.3324/haematol.2014.109884. Epub 2014 Nov 25. PubMed PMID: 25425682; PubMed
Central PMCID: PMC4803136.


Guillemette C, Lévesque É, Rouleau M. Pharmacogenomics of human uridine
diphospho-glucuronosyltransferases and clinical implications. Clin Pharmacol
Ther. 2014 Sep;96(3):324-39. doi: 10.1038/clpt.2014.126. Epub 2014 Jun 12. PubMed
PMID: 24922307.


Lévesque E, Laverdière I, Audet-Walsh E, Caron P, Rouleau M, Fradet Y,
Lacombe L, Guillemette C. Steroidogenic germline polymorphism predictors of
prostate cancer progression in the estradiol pathway. Clin Cancer Res. 2014 Jun
1;20(11):2971-83. doi: 10.1158/1078-0432.CCR-13-2567. Epub 2014 Mar 28. PubMed
PMID: 24682418.


Lévesque É, Laverdière I, Lacombe L, Caron P, Rouleau M, Turcotte V, Têtu B,
Fradet Y, Guillemette C. Importance of 5α-reductase gene polymorphisms on
circulating and intraprostatic androgens in prostate cancer. Clin Cancer Res.
2014 Feb 1;20(3):576-84. doi: 10.1158/1078-0432.CCR-13-1100. Epub 2013 Nov 25.
PubMed PMID: 24277450.


Ménard V, Lévesque E, Chen S, Eap O, Joy MS, Ekström L, Rane A, Guillemette
C. Expression of UGT2B7 is driven by two mutually exclusive promoters and
alternative splicing in human tissues: changes from prenatal life to adulthood
and in kidney cancer. Pharmacogenet Genomics. 2013 Dec;23(12):684-96. doi:
10.1097/FPC.0000000000000008. PubMed PMID: 24128937.


Lévesque E, Bélanger AS, Harvey M, Couture F, Jonker D, Innocenti F, Cecchin
E, Toffoli G, Guillemette C. Refining the UGT1A haplotype associated with
irinotecan-induced hematological toxicity in metastatic colorectal cancer
patients treated with 5-fluorouracil/irinotecan-based regimens. J Pharmacol Exp
Ther. 2013 Apr;345(1):95-101. doi: 10.1124/jpet.112.202242. Epub 2013 Feb 5.
PubMed PMID: 23386248; PubMed Central PMCID: PMC3920089.


Lévesque É, Huang SP, Audet-Walsh É, Lacombe L, Bao BY, Fradet Y, Laverdière
I, Rouleau M, Huang CY, Yu CC, Caron P, Guillemette C. Molecular markers in key
steroidogenic pathways, circulating steroid levels, and prostate cancer
progression. Clin Cancer Res. 2013 Feb 1;19(3):699-709. doi:
10.1158/1078-0432.CCR-12-2812. Epub 2012 Nov 27. PubMed PMID: 23186779.


Gruber M, Bellemare J, Hoermann G, Gleiss A, Porpaczy E, Bilban M, Le T,
Zehetmayer S, Mannhalter C, Gaiger A, Shehata M, Fleiss K, Skrabs C, Lévesque É,
Vanura K, Guillemette C, Jaeger U. Overexpression of uridine diphospho
glucuronosyltransferase 2B17 in high-risk chronic lymphocytic leukemia. Blood.
2013 Feb 14;121(7):1175-83. doi: 10.1182/blood-2012-08-447359. Epub 2012 Nov 20.
PubMed PMID: 23169782.


Laverdière I, Caron P, Couture F, Lévesque E, Guillemette C. A liquid
chromatography-tandem mass spectrometry (LC-MS/MS) method for monitoring drug
exposure in hematopoietic stem cell transplant recipients. J Chromatogr B Analyt
Technol Biomed Life Sci. 2012 Feb 15;885-886:131-7. doi:
10.1016/j.jchromb.2011.12.029. Epub 2012 Jan 9. PubMed PMID: 22265668.


Audet-Walsh É, Bellemare J, Lacombe L, Fradet Y, Fradet V, Douville P,
Guillemette C, Lévesque É. The impact of germline genetic variations in
hydroxysteroid (17-beta) dehydrogenases on prostate cancer outcomes after
prostatectomy. Eur Urol. 2012 Jul;62(1):88-96. doi: 10.1016/j.eururo.2011.12.021.
Epub 2011 Dec 21. PubMed PMID: 22209174.

Laverdière I, Caron P, Couture F, Guillemette C, Lévesque E. Liquid
chromatography-coupled tandem mass spectrometry based assay to evaluate
inosine-5′-monophosphate dehydrogenase activity in peripheral blood mononuclear
cells from stem cell transplant recipients. Anal Chem. 2012 Jan 3;84(1):216-23.
doi: 10.1021/ac202404y. Epub 2011 Dec 2. PubMed PMID: 22092180.


Ménard V, Eap O, Roberge J, Harvey M, Lévesque E, Guillemette C.
Transcriptional diversity at the UGT2B7 locus is dictated by extensive pre-mRNA
splicing mechanisms that give rise to multiple mRNA splice variants.
Pharmacogenet Genomics. 2011 Oct;21(10):631-41. doi:
10.1097/FPC.0b013e3283498147. PubMed PMID: 21881541.